Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (AURA) is a clinical-stage biotechnology company pioneering precision therapies that target solid tumors while preserving critical organ function. This page serves as the definitive source for investors and medical professionals tracking the company's progress in ocular oncology and bladder cancer treatments.
Access real-time updates on clinical trial developments, regulatory milestones, and strategic partnerships. Our curated news collection includes press releases covering drug candidate advancements (including lead program bel-sar), financial disclosures, and scientific presentations—all essential for evaluating AURA's position in targeted cancer therapeutics.
Key content categories include clinical trial phase updates, FDA designation announcements, collaborative research initiatives, and financial performance reports. The company's innovative molecular surgery approach—combining direct tumor targeting with immune activation—is reflected across all coverage.
Bookmark this page for streamlined monitoring of AURA's progress in vision-preserving ocular melanoma treatments and organ-sparing bladder cancer therapies. Check regularly for authoritative updates on this clinical-stage innovator's journey through the drug development pipeline.
Aura Biosciences (NASDAQ: AURA) reported Q3 2024 financial results and clinical progress. The company presented positive Phase 2 end-of-study data for bel-sar in early-stage choroidal melanoma, showing 80% tumor control rate and 90% visual acuity preservation. In the Phase 1 trial for bladder cancer, 4 out of 5 patients with low-grade disease achieved complete response. The company's cash position of $174.4 million is expected to fund operations into 2H 2026. Q3 net loss increased to $21.0 million from $18.5 million year-over-year, with R&D expenses at $17.0 million and G&A expenses at $6.2 million.
Aura Biosciences (NASDAQ: AURA) announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with Non-Muscle-Invasive Bladder Cancer (NMIBC). The trial includes 13 patients, evaluating safety and feasibility of local administration of bel-sar alone and with light activation. Key findings include:
- 4 out of 5 patients with low grade disease demonstrated a clinical complete response
- 2 out of 3 patients with high grade disease showed visual tumor shrinkage
- Favorable safety profile with only Grade 1 drug-related adverse events reported in less than 10% of patients
- Evidence of bladder urothelial field effect in non-target tumors
Bel-sar, a virus-like drug conjugate, shows potential as a transformative cancer treatment with rapid tumor response and immune oncology effect. Aura is preparing for a Phase 2 trial to further evaluate bel-sar's clinical activity and durability of response.
Aura Biosciences (NASDAQ: AURA) reported positive Phase 2 end of study results for bel-sar (AU-011) in treating early-stage choroidal melanoma (CM). The study showed an 80% tumor control rate and 90% visual acuity preservation among Phase 3-eligible patients. Bel-sar demonstrated a highly favorable safety profile with no treatment-related serious adverse events. The drug achieved complete cessation of growth in responders, with a post-treatment average growth rate of 0.011 mm/yr compared to 0.351 mm/yr prior to study entry (p<0.0001). Notably, 80% of patients were at high risk for vision loss due to tumor proximity to critical eye structures. These results are significant given the poor prognosis associated with CM and the lack of approved vision-preserving therapies. Aura is currently enrolling patients in the global Phase 3 CoMpass trial for bel-sar.
Aura Biosciences (NASDAQ: AURA) announced a virtual urologic oncology investor event on October 17, 2024, to present early Non-Muscle Invasive Bladder Cancer (NMIBC) data from its ongoing Phase 1 trial. The event will feature key opinion leaders discussing the trial data, unmet medical needs, and current NMIBC treatment landscape. The Phase 1 trial is evaluating bel-sar (AU-011), a novel virus-like drug conjugate, as a monotherapy prior to standard care.
Additionally, Aura announced that Dr. Sabine Brookman-May will join as Senior Vice President, Clinical Development Urologic Oncology in October 2024. Dr. Brookman-May brings over 20 years of experience in urology and will lead Aura's urologic oncology therapeutic area, focusing on developing bel-sar for bladder cancer treatment.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company developing precision therapies for solid tumors, has announced its participation in two upcoming investor conferences. The company will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, where senior management will engage in one-on-one investor meetings. Additionally, Aura will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, featuring both investor meetings and a virtual presentation by CEO Elisabet de los Pinos, PhD.
The virtual presentation at the H.C. Wainwright conference will be available at 7:00 am ET on September 9, 2024, accessible via the company's website and the conference platform. This presentation will remain archived on Aura's website for 90 days following the event, providing extended access for interested parties.
Aura Biosciences (NASDAQ: AURA) announced the upcoming presentation of Phase 2 end of study data for bel-sar, a treatment for early-stage choroidal melanoma, at The Retina Society Annual Meeting in Lisbon, Portugal. The presentation, titled 'Final Results of a Phase 2 Trial of Suprachoroidal Administration of Belzupacap Sarotalocan (bel-sar, AU-011) for Choroidal Melanoma', will be given by Dr. Ivana Kim on September 12, 2024.
Additionally, Aura will host a virtual ocular oncology investor event on the same day, featuring Dr. Kim and Dr. Prithvi Mruthyunjaya, to discuss the Phase 2 data. The event will include a live Q&A session and will be available for replay on Aura's website for 90 days.
Aura Biosciences (NASDAQ: AURA) reported Q2 2024 financial results and business highlights. Key points include:
1. Early Non-muscle Invasive Bladder Cancer (NMIBC) data from ongoing Phase 1 trial to be presented in October 2024.
2. Phase 2 end of study data for choroidal melanoma treatment to be presented in September 2024.
3. Strong cash position of $187.4 million, expected to fund operations into second half of 2026.
4. Q2 2024 financial results: R&D expenses increased to $16.9 million, G&A expenses rose to $5.9 million, net loss was $20.3 million.
5. Ongoing clinical trials in ocular and urologic oncology, with potential for new treatment options.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors, announced participation in the Jefferies Global Healthcare Conference. CEO Elisabet de los Pinos will present on June 6, 2024, at 12:30 p.m. ET. The presentation will be webcast live and available on Aura Biosciences' website, with a replay accessible for 90 days post-event.
Aura Biosciences will host a virtual KOL event titled “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024, at 2:00 PM ET.
Experts including Dr. Carol Shields, Dr. Hakan Demirci, and Dr. Mandeep Sagoo will discuss the unmet medical needs and current treatments for ocular cancers like primary uveal melanoma and metastases to the choroid. The event will spotlight Aura's lead candidate, bel-sar, which is in a Phase 3 trial for early-stage uveal melanoma.
The event will feature a panel discussion moderated by Chris Howerton and will include a live Q&A session. The webcast will be available on Aura's website and archived for 90 days.
Aura Biosciences, Inc. (NASDAQ: AURA) reported financial results for Q1 2024, highlighting progress in ocular and urologic oncology programs. The company is enrolling in a Phase 3 trial for small choroidal melanoma, with positive pipeline developments in bel-sar treatments for various ocular cancers and bladder cancer. Aura has a strong cash position expected to fund operations until H2 2026.
FAQ
What is the current stock price of Aura Biosciences (AURA)?
What is the market cap of Aura Biosciences (AURA)?
